And that ends starting today. The other countries are not happy with us. I don't think they like me too much, Bobby, but that's okay. Eli Lilly and Novo Nordisk are committing to offer Zepbound and WeGovy at most favored nations rates for American patients. This will slash the cost of WeGovy from $1,350 a month to ultimately $250 a month. $1,350 to $250. Did I do a good job? They don't write about it. (04:52–05:02)
CLAIM
Asserts that these companies will offer drugs at reduced rates for American patients.
This is an excerpt from a raw transcript. The assertions have not been audited or verified. Tap the video to view the source footage and understand the context.
